Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK 0677

Known as: MK 677, MK-0677, MK-677 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ibutamoren mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… Expand
Highly Cited
2004
Highly Cited
2004
The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture
Objectives: To evaluate the effects of MK‐0677, an orally active growth hormone (GH) secretagogue, on functional recovery from… Expand
Highly Cited
2001
Highly Cited
2001
Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
GH increases bone turnover and stimulates osteoblast activity. We hypothesized that administration of MK-677, an orally active GH… Expand
Highly Cited
1998
Highly Cited
1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… Expand
Highly Cited
1998
Highly Cited
1998
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
1998
1998
Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males
The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK‐677 on markers of bone metabolism was… Expand
Highly Cited
1997
Highly Cited
1997
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Previous studies have indicated the existence of common mechanisms regulating sleep and somatotropic activity. In the present… Expand
Highly Cited
1996
Highly Cited
1996
Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young…
To assess the effects of prolonged administration of a novel analog of GH-releasing peptide (MK-677), nine healthy young men… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • table 2
Highly Cited
1996
Highly Cited
1996
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Aging is associated with declining activity of the GH axis, possibly contributing to adverse body composition changes and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
1996
1996
MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
MK-0677, a spiroindoline sulfonamide, is a novel, orally active GH secretagogue. The effects of MK-0677 on serum GH and other… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE